VX15-770-126 A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have a CFTR Gating Mutation
What is the goal of the study?
To learn more about this study, please email the study team member listed below.
Who can participate in the study?
Please contact the study team listed below to learn more.